A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics of Single Dose and 7-day Repeat Doses of PA9159 Nasal Spray in Healthy Chinese Adult
Latest Information Update: 22 Jan 2026
At a glance
- Drugs PA 9159 (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Adverse reactions
- Sponsors Anhui Palo Alto Pharmaceuticals
Most Recent Events
- 22 Jan 2026 New trial record